Track market-moving stories before they get noisy

A month has gone by since the last earnings report for Charles River Laboratories (CRL - Free Report) . Shares have added about 10.5% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Charles River due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for Charles River Laboratories International, Inc. before we dive into how investors and analysts have reacted as of late.

CRL Q2 Earnings and Revenues Top, '26 View UpCharles River reported second-quarter 2026 company-defined non-GAAP earnings of $3.02 per share, down 3.2% year over year. The reported earnings topped the Zacks Consensus Estimate by 11.0%.

GAAP net loss was 3 cents per share compared to GAAP earnings of $1.06 per share in the year-ago period.

Revenues of $1 billion declined 2.7% (up 0.1% organically) year over year but beat the Zacks Consensus Estimate by 3%. 

Charles River's DSA Business Shows Demand GainsDSA revenues totaled $606.5 million, down 1.9% year over year on a reported basis. Organic revenues increased 0.2%, driven mainly by higher study volume for regulated safety assessment services.

The segment's GAAP operating margin rose 60 basis points to 20.5%, aided by lower intangible-asset amortization and reduced third-party legal costs tied to a non-human primate supply matter. The non-GAAP margin fell 180 basis points to 25.6% because of higher study-related direct costs.

CRL's RMS Sales Decline on North America WeaknessRMS revenues totaled $209.5 million, down 1.8% from the year-ago quarter’s level. Organic revenues declined 1.4% primarily due to lower sales of small research models in North America and weaker research model services, partly offset by growth in China.

The segment's GAAP operating margin improved 50 basis points to 17.3%, mainly because of lower amortization following the Cell Solutions divestiture. The non-GAAP margin contracted 80 basis points to 24.5% on lower volume and an unfavorable geographic revenue mix.

Charles River's Manufacturing Margins ExpandManufacturing revenues amounted to $188.1 million, down 6.3% year over year, mainly because of the CDMO divestiture. Organic revenues rose 1.3%, supported by higher revenues in the Microbial Solutions business.

GAAP operating margin surged to 34.9% from 6% a year earlier. The non-GAAP margin expanded 500 basis points to 37.8%, with the CDMO business and the benefit from its divestiture driving the improvement.

CRL's Margin PerformanceThe gross profit in the reported quarter was $363.4 million, up 1.8% from the prior-year quarter’s level. The gross margin of 36.2% expanded approximately 159 basis points (bps) year over year.

Selling, general and administrative expenses increased 19.5% year over year to $228.9 million. Operating profit totaled $119.9 million, up 19.7% from the prior-year quarter’s level. The operating margin expanded approximately 224 bps to 11.9%.

 CRL's Cash Flow and Buyback ActivityCash and cash equivalents amounted to $192 million as of June 27, 2026, compared with $191.8 million at the end of the first quarter. Cumulative net cash provided by operating activities at the end of the quarter was $220.8 million compared with $376.3 million a year ago.

CRL repurchased 0.6 million shares for $100 million during the second quarter at an average price of $174 per share. Year-to-date repurchases totaled $300 million, leaving $700 million available under the company's authorization.

Charles River Raises Its 2026 OutlookCharles River now expects reported revenues to decline 3.5% to 2.5% in 2026, compared with its prior projection for a 5.5% to 4% decrease. The Zacks Consensus Estimate for 2026 revenues implies a decline of 3% year over year. 

The company raised its non-GAAP earnings guidance to $11.15-$11.45 per share from $10.80-$11.30. The Zacks Consensus Estimate for the metric is pegged at $11.28 per share.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in estimates revision.

VGM ScoresCurrently, Charles River has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a score of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Charles River has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.

Performance of an Industry PlayerCharles River is part of the Zacks Medical Services industry. Over the past month, HCA Healthcare (HCA - Free Report) , a stock from the same industry, has gained 0.1%. The company reported its results for the quarter ended June 2026 more than a month ago.

HCA reported revenues of $20.23 billion in the last reported quarter, representing a year-over-year change of +8.7%. EPS of $7.59 for the same period compares with $6.84 a year ago.

HCA is expected to post earnings of $6.80 per share for the current quarter, representing a year-over-year change of -2.3%. Over the last 30 days, the Zacks Consensus Estimate has changed -2.8%.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for HCA. Also, the stock has a VGM Score of B.

Charles River Laboratories International (NYSE:CRL – Get Free Report) and IB Acquisition (NASDAQ:IBAC – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Earnings and Valuation This table compares Charles River Laboratories International and IB Acquisition”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Charles River Laboratories International $4.02 billion 3.47 -$144.34 million ($4.85) -60.16 IB Acquisition N/A N/A N/A N/A N/A IB Acquisition has lower revenue, but higher earnings than Charles River Laboratories International. Analyst Ratings This is a breakdown of current recommendations and price targets for Charles River Laboratories International and IB Acquisition, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Charles River Laboratories International 1 3 12 0 2.69 IB Acquisition 1 0 0 0 1.00 Charles River Laboratories International currently has a consensus target price of $255.65, indicating a potential downside of 12.39%. Given Charles River Laboratories International’s stronger consensus rating and higher possible upside, analysts plainly believe Charles River Laboratories International is more favorable than IB Acquisition.

Profitability This table compares Charles River Laboratories International and IB Acquisition’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Charles River Laboratories International -5.96% 15.75% 6.51% IB Acquisition N/A N/A N/A Institutional & Insider Ownership 98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary Charles River Laboratories International beats IB Acquisition on 8 of the 9 factors compared between the two stocks.

(Get Free Report)

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

About IB Acquisition (Get Free Report)

IB Acquisition Corp. is a blank check company. It formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses or entities. IB Acquisition Corp. is based in Boca Raton, Florida.

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Charles River's shares rose 88.6% in a year, outperforming the industry's 11.5% rise.CRL's DSA organic revenues returned to growth as Q2 bookings rose 12.6% sequentially to $701 million. Charles River is expanding new testing approaches through PathoQuest, Arovella and Lilly's TuneLab. Charles River Laboratories International (CRL - Free Report) has witnessed strong momentum over the past year. Shares of the company have risen 88.6%, outperforming the industry’s 11.5% growth. The S&P 500 composite has increased 23.4% during the same time frame.

With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.

Charles River is a full-service, early-stage contract research organization, headquartered in Wilmington, MA. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. It has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (“GLP”) and non-GLP. Charles River currently has three reporting segments - Discovery and Safety Assessment (“DSA”), Research Models and Services (“RMS”) and Manufacturing Solutions.

Factors Favoring CRL’s Share Price GrowthCharles River’s share price is trending upward, prompted by its strong DSA segment’s quarterly performance. In the second quarter of 2026, DSA organic revenues increased 0.2%, its first organic growth since the third quarter of 2023. Net bookings rose 12.6% sequentially to $701 million, backlog increased to $1.97 billion and net book-to-bill reached 1.19x, marking the third consecutive quarter above 1x and the highest level in nearly four years. This improvement was broad-based across global biopharma and small and midsized biotech clients.

Additionally, the company’s gradual, long-term shift toward broader adoption of new approach methodologies looks encouraging. PathoQuest adds next-generation sequencing capabilities for in vitro testing and a new Arovella Therapeutics collaboration extends those capabilities into cell and gene therapy programs. Charles River also joined Eli Lilly’s TuneLab platform to contribute non-clinical testing expertise to AI and machine-learning drug discovery. These initiatives complement virtual control groups and the AMAP program, reinforcing a strategy that combines in vivo, in vitro and data-driven approaches.

Image Source: Zacks Investment Research

From a solvency viewpoint, Charles River exited the second quarter of 2026 with cash and cash equivalents of $192 million, with no short-term debt payable. This is good news in terms of the company’s solvency position, particularly during the time of worldwide macroeconomic complications. The debt-to-capital ratio was 47.9% in the first quarter. The company repurchased $300 million of stock in the first half, including $100 million in the second quarter, leaving $700 million under its authorization while continuing to fund organic investment, acquisitions and debt repayment.

Factors That May Offset CRL’s GainsCharles River’s safety assessment and large-model activities remain exposed to variability in NHP sourcing, study mix and study-start costs. In the second quarter of 2026, DSA operating margin fell 180 basis points year over year to 25.6%, primarily because of higher study-related direct costs, even as NHP shipment timing normalized in RMS. 

Additionally, the company competes on scientific expertise, quality, responsiveness, innovation, capacity and price across its business segments. Clients can still compare providers on price, capacity and technical capability, particularly in discretionary discovery work. If demand recovery remains gradual, the cost of maintaining technology, scientific talent and client support could limit operating leverage even as Charles River refines its portfolio.

Taking a Look at CRL’s EstimatesThe Zacks Consensus Estimate for 2026 earnings has moved north 2.1% to $11.28 in the past 30 days.

The company has an estimated long-term EPS growth rate of 8.5% compared with the industry’s 13.6% growth. 

Other Stocks to ConsiderSome other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Teleflex (TFX - Free Report) .

Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% fall over the past year.

GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Veracyte, sporting a Zacks Rank #1, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

Teleflex, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX’s shares have rallied 5% against the industry’s 6.2% decline over the past year.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC's next-generation multivalent.

Posted by Defense World Staff on Aug 11th, 2026

Shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) hit a new 52-week high on Tuesday . The company traded as high as $277.07 and last traded at $276.34, with a volume of 1025310 shares trading hands. The stock had previously closed at $267.49.

Analyst Ratings Changes CRL has been the subject of a number of research reports. Royal Bank Of Canada upped their target price on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the stock an “outperform” rating in a report on Thursday. TD Cowen raised their price target on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the stock a “buy” rating in a research note on Monday. Morgan Stanley boosted their price target on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a research report on Friday. Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a research note on Monday. Finally, Sanford C. Bernstein set a $250.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $255.65.

Get Our Latest Stock Report on CRL

Charles River Laboratories International Stock Performance The firm has a fifty day moving average price of $216.74 and a 200 day moving average price of $189.45. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The firm has a market cap of $13.19 billion, a PE ratio of -56.98, a price-to-earnings-growth ratio of 2.77 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same quarter in the prior year, the firm posted $3.12 earnings per share. Charles River Laboratories International’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current fiscal year.

Insider Activity In other news, Director James C. Foster sold 75,000 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the completion of the sale, the director owned 31,596 shares of the company’s stock, valued at $7,109,100. This represents a 70.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 5,046 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the sale, the executive vice president owned 4,807 shares of the company’s stock, valued at $1,264,241. This represents a 51.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 90,870 shares of company stock worth $21,015,353. Corporate insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Charles River Laboratories International Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. grew its stake in shares of Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after acquiring an additional 1,446,972 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $176,478,000. Victory Capital Management Inc. raised its stake in shares of Charles River Laboratories International by 9,938.8% in the fourth quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock valued at $137,935,000 after acquiring an additional 684,586 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in Charles River Laboratories International by 1,491.1% in the third quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after purchasing an additional 575,039 shares during the period. Finally, Amundi boosted its holdings in Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after purchasing an additional 492,301 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile (Get Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

Read More Five stocks we like better than Charles River Laboratories International SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat 3 Dividend Champion Utilities for a Market That Can’t Sit Still These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI First Solar’s Profit Engine Faces a New Policy Test in Washington Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAtreides Management LP Buys 265,761 Shares of Amazon.com, Inc. $AMZN

The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?Charles River Laboratories International NYSE: CRL reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earnings and free-cash-flow guidance while maintaining a cautious view that the recovery in biopharmaceutical demand will progress gradually.

Chief Executive Officer Birgit Girshick said total company organic revenue increased 0.1% year over year, marking the first quarter of organic revenue growth since the third quarter of 2023. Non-GAAP earnings per share totaled $3.02, up 47% sequentially and above the company’s prior expectation for at least 30% sequential growth.

Get CRL alerts:

“We were encouraged that the biopharmaceutical demand environment continued to strengthen in the second quarter, particularly in the DSA segment,” Girshick said. DSA net book-to-bill reached nearly 1.2 times, its highest level in almost four years and the third straight quarter above 1.0 times.

DSA bookings and backlog improve DSA organic revenue rose 0.2% in the second quarter, ending a stretch of declines that began after the third quarter of 2023. Reported DSA revenue was $607 million, down 1.9% because of the divestiture of certain European discovery sites.

Net DSA bookings increased 12.6% sequentially to $701 million, raising backlog to $1.97 billion. The segment’s net book-to-bill ratio was 1.19 times, supported by both global biopharmaceutical customers and small- and midsize-biotechnology clients.

Girshick said the company is beginning to see revenue benefits from bookings made late last year, while more recent booking strength is expected to support additional growth in the second half and into 2027. DSA demand was broad-based across study types and modalities, including increased activity in IND-enabling work and continued demand for non-human-primate, or NHP, studies tied to complex biologics.

The company said its ownership of NHP suppliers in Mauritius and Cambodia has strengthened its supply-chain control and competitive position. Girshick said the company can manage NHP availability, shipment timing and quality more directly, though some third-party supply contracts will continue to wind down over the next several years.

DSA operating margin was 25.6%, down 180 basis points year over year because of higher study-related direct costs but up 460 basis points sequentially. Chief Financial Officer Glenn Coleman said lower sourcing costs from the company’s Cambodian NHP supplier acquisition are expected to begin benefiting margins in the third quarter and have a more meaningful effect in the fourth quarter as more of those animals are placed on studies.

Portfolio changes lift margins The company completed divestitures of certain European discovery services sites, its CDMO business and its Cell Solutions business during May. Girshick said the moves refined the company’s portfolio around regulated testing capabilities and contributed to a 420-basis-point sequential improvement in consolidated operating margin to 20.5%.

Manufacturing revenue was $188 million and rose 1.3% organically. Excluding CDMO, which remained part of the business for a portion of the quarter before its divestiture, the segment grew at a mid-single-digit organic rate. Microbial Solutions delivered high-single-digit organic growth, driven by demand across regions for endotoxin-testing reagents and rapid testing cartridges.

Manufacturing operating margin increased 500 basis points year over year to 37.8%, primarily reflecting the CDMO divestiture. Coleman said the segment’s margin could approach 40% in the second half as the company receives the full-period benefit from that transaction.

Research Models and Services, or RMS, revenue declined 1.4% organically to $209 million. The decline reflected lower North American small-model volumes and lower revenue from research model services, including genetically engineered models and services. Strong demand from mid-tier biotech and contract research organization clients in China partly offset those declines.

Girshick said academic and government demand in North America remained stable but was not growing, with flat National Institutes of Health budgets and slower grant processing affecting the market. The company maintained its expectation for a low- to mid-single-digit organic RMS revenue decline for the year.

Guidance raised for 2026 Charles River raised its 2026 organic revenue outlook to a range of flat to 1% growth, a 150-basis-point improvement from its prior outlook. Reported revenue is now expected to decline 2.5% to 3.5%, largely due to completed divestitures.

DSA organic revenue is now expected to grow at a low-single-digit rate for the full year. Manufacturing organic revenue is expected to grow at a low- to mid-single-digit rate. RMS guidance was unchanged, with a low- to mid-single-digit organic decline anticipated. Non-GAAP EPS guidance was raised to $11.15 to $11.45, representing 8% to 11% year-over-year growth. Free cash flow guidance was raised to $400 million to $420 million from $375 million to $400 million. The company maintained its expectation for 120 to 150 basis points of full-year operating-margin expansion. Coleman said management has “a clear line of sight” to at least 500 basis points of margin improvement in the second half compared with the first half, driven by portfolio actions, lower NHP sourcing costs, reduced corporate costs and efficiency initiatives.

For the third quarter, Charles River expects reported revenue to decline 4% to 6%, reflecting divestitures, while organic revenue is projected to rise 1% to 3%. It forecast third-quarter non-GAAP EPS of $2.90 to $3.00.

Technology and client partnerships Girshick highlighted collaborations with Eli Lilly’s TuneLab drug-discovery platform and Arovella Therapeutics as examples of the company’s strategy to combine traditional testing with newer technologies. Through the Lilly collaboration, Charles River will provide non-clinical testing expertise to help optimize Lilly’s artificial-intelligence and machine-learning drug-discovery model.

The company is also expanding bioanalytical laboratory capacity in Scotland at Heriot-Watt University’s Research Park, part of five ongoing global lab-science expansions. Charles River is investing in AI-enabled digital pathology workflows, with a goal of reducing standard pathology timelines by at least one week for clients using its fully integrated solution.

Girshick said AI could become a long-term demand tailwind if more efficient molecule design and target identification lead to additional programs reaching validation and regulated safety-assessment stages. She said the timing of a material impact remains difficult to estimate but that AI-native drug discovery companies are already tending to run more programs than typical early-stage biotech clients.

About Charles River Laboratories International (NYSE:CRL)Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Charles River Laboratories International Right Now?Before you consider Charles River Laboratories International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.

While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Charles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcript

For the quarter ended June 2026, Charles River Laboratories (CRL - Free Report) reported revenue of $1 billion, down 2.7% over the same period last year. EPS came in at $3.02, compared to $3.12 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $970.77 million, representing a surprise of +3.43%. The company delivered an EPS surprise of +11.03%, with the consensus EPS estimate being $2.72.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Charles River performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenue- Research Models and Services: $209.48 million versus $199.8 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -1.8% change.Revenue- Manufacturing Solutions: $188.1 million compared to the $185.04 million average estimate based on three analysts. The reported number represents a change of -6.3% year over year.Revenue- Discovery and Safety Assessment: $606.51 million versus the three-analyst average estimate of $582.7 million. The reported number represents a year-over-year change of -1.9%.Operating income- Manufacturing Solutions- Non-GAAP: $71.15 million versus the three-analyst average estimate of $55.38 million.Operating income- Discovery and Safety Assessment- Non-GAAP: $155.32 million compared to the $149.55 million average estimate based on three analysts.Operating income- Research Models and Services- Non-GAAP: $51.25 million versus the three-analyst average estimate of $50.04 million.Operating income- Discovery and Safety Assessment: $124.4 million versus $123.97 million estimated by two analysts on average.Operating income- Research Models and Services: $36.28 million compared to the $31.2 million average estimate based on two analysts.Operating income- Manufacturing Solutions: $65.61 million versus $44.17 million estimated by two analysts on average.Operating income- Unallocated Corporate Overhead: $-106.39 million versus the two-analyst average estimate of $-65.34 million.View all Key Company Metrics for Charles River here>>>

Shares of Charles River have returned +2.4% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Charles River Laboratories (CRL - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Charles River Laboratories is a member of the Medical sector. This group includes 914 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Charles River Laboratories is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for CRL's full-year earnings has moved 0.8% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

According to our latest data, CRL has moved about 17.4% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 0.3% on average. This means that Charles River Laboratories is outperforming the sector as a whole this year.

Another stock in the Medical sector, Curaleaf Holdings, Inc. (CURLF - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 19.2%.

Over the past three months, Curaleaf Holdings, Inc.'s consensus EPS estimate for the current year has increased 33.8%. The stock currently has a Zacks Rank #1 (Strong Buy).

Looking more specifically, Charles River Laboratories belongs to the Medical Services industry, a group that includes 72 individual stocks and currently sits at #92 in the Zacks Industry Rank. This group has gained an average of 0% so far this year, so CRL is performing better in this area.

In contrast, Curaleaf Holdings, Inc. falls under the Medical - Products industry. Currently, this industry has 84 stocks and is ranked #157. Since the beginning of the year, the industry has moved -16.5%.

Investors with an interest in Medical stocks should continue to track Charles River Laboratories and Curaleaf Holdings, Inc.. These stocks will be looking to continue their solid performance.

Contract drug developer Charles River Laboratories on Wednesday raised its annual profit forecast after quarterly results ​beat estimates, as it banked on stronger demand ‌for its drug discovery and development services from biotech clients.

Posted by Defense World Staff on Aug 1st, 2026

Avidity Partners Management LP bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 10,000 shares of the medical research company’s stock, valued at approximately $1,670,000.

Several other hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Charles River Laboratories International by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock valued at $1,174,374,000 after buying an additional 47,432 shares during the period. Aberdeen Group plc lifted its stake in shares of Charles River Laboratories International by 1,090.5% during the fourth quarter. Aberdeen Group plc now owns 97,001 shares of the medical research company’s stock worth $19,350,000 after purchasing an additional 88,853 shares in the last quarter. Assetmark Inc. boosted its holdings in Charles River Laboratories International by 17.9% in the 4th quarter. Assetmark Inc. now owns 43,809 shares of the medical research company’s stock worth $8,739,000 after acquiring an additional 6,666 shares during the period. Eos Management L.P. purchased a new position in Charles River Laboratories International in the 4th quarter valued at about $839,000. Finally, M&T Bank Corp lifted its stake in shares of Charles River Laboratories International by 1,424.9% in the fourth quarter. M&T Bank Corp now owns 27,997 shares of the medical research company’s stock worth $5,585,000 after acquiring an additional 26,161 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes A number of research analysts have commented on the stock. Barclays increased their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Sanford C. Bernstein set a $250.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Finally, JPMorgan Chase & Co. cut their target price on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Monday, April 13th. Eleven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International has an average rating of “Moderate Buy” and an average target price of $220.75.

Get Our Latest Analysis on CRL

Insider Activity In other news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the sale, the director owned 31,596 shares in the company, valued at approximately $7,109,100. The trade was a 70.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance Shares of NYSE CRL opened at $232.49 on Friday. The firm has a market capitalization of $11.20 billion, a price-to-earnings ratio of -61.83, a PEG ratio of 2.61 and a beta of 1.40. The business has a fifty day simple moving average of $206.60 and a 200 day simple moving average of $188.14. Charles River Laboratories International, Inc. has a one year low of $144.26 and a one year high of $242.73. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.10. The firm had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.05 EPS for the current year.

About Charles River Laboratories International (Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

Recommended Stories Five stocks we like better than Charles River Laboratories International Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case Apple’s Record Quarter Could Not Outrun Its Guidance Problem McKesson’s Compounding Keeps Adding Up

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAvidity Partners Management LP Buys Shares of 25,000 Humana Inc. $HUM

NEXT HEADLINE »Avidity Partners Management LP Sells 7,600 Shares of Medtronic PLC $MDT

The market expects Charles River Laboratories (CRL - Free Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 5. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis medical research equipment and services provider is expected to post quarterly earnings of $2.72 per share in its upcoming report, which represents a year-over-year change of -12.8%.

Revenues are expected to be $970.77 million, down 6% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.72% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Charles River?For Charles River, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +1.43%.

On the other hand, the stock currently carries a Zacks Rank of #2.

So, this combination indicates that Charles River will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Charles River would post earnings of $1.96 per share when it actually produced earnings of $2.06, delivering a surprise of +5.10%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Charles River appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsArdent Health, Inc. (ARDT - Free Report) , another stock in the Zacks Medical Services industry, is expected to report earnings per share of $0.17 for the quarter ended June 2026. This estimate points to a year-over-year change of -67.3%. Revenues for the quarter are expected to be $1.59 billion, down 3.3% from the year-ago quarter.

The consensus EPS estimate for Ardent Health, Inc. has been revised 2.1% higher over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +5.00%.

This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that Ardent Health, Inc. will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Posted by Defense World Staff on Jul 27th, 2026

Epoch Investment Partners Inc. reduced its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 77.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,308 shares of the medical research company’s stock after selling 21,131 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Charles River Laboratories International were worth $1,088,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Charles River Laboratories International by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock valued at $1,174,374,000 after acquiring an additional 47,432 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Charles River Laboratories International by 115.8% during the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after purchasing an additional 1,446,972 shares in the last quarter. State Street Corp boosted its stake in shares of Charles River Laboratories International by 2.2% during the 4th quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock valued at $373,364,000 after purchasing an additional 40,535 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Charles River Laboratories International by 14.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after buying an additional 210,260 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Charles River Laboratories International by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock valued at $254,186,000 after buying an additional 9,756 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Activity In other news, Director James C. Foster sold 75,000 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at $7,109,100. The trade was a 70.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Down 0.1% CRL stock opened at $226.38 on Monday. The stock has a market capitalization of $10.90 billion, a P/E ratio of -60.21, a P/E/G ratio of 2.52 and a beta of 1.40. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $238.85. The business has a fifty day moving average price of $198.80 and a 200-day moving average price of $187.36.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. During the same period last year, the company earned $2.34 EPS. Charles River Laboratories International’s revenue for the quarter was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities analysts forecast that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades CRL has been the subject of several research analyst reports. Evercore restated an “outperform” rating and issued a $220.00 price objective on shares of Charles River Laboratories International in a report on Friday, May 8th. Royal Bank Of Canada initiated coverage on Charles River Laboratories International in a research report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 target price for the company. Morgan Stanley raised their target price on Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Mizuho boosted their target price on Charles River Laboratories International from $192.00 to $230.00 and gave the stock a “neutral” rating in a report on Monday, July 13th. Finally, Weiss Ratings raised Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $220.75.

Get Our Latest Stock Analysis on CRL

Charles River Laboratories International Company Profile (Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

Featured Articles Five stocks we like better than Charles River Laboratories International RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? These 4 Earnings Reports Expose the Market’s Growing Economic Divide Broadcom May Be the Biggest Winner From Alphabet’s Earnings Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBradley Foster & Sargent Inc. CT Grows Position in iShares MSCI ACWI ex U.S. ETF $ACWX

NEXT HEADLINE »iShares Currency Hedged MSCI Japan ETF (NYSEARCA:HEWJ) Short Interest Up 799.2% in July

Posted by Defense World Staff on Jul 21st, 2026

Fifth Third Bancorp grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 51.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,733 shares of the medical research company’s stock after acquiring an additional 6,002 shares during the quarter. Fifth Third Bancorp’s holdings in Charles River Laboratories International were worth $3,059,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in CRL. Tema Etfs LLC bought a new position in Charles River Laboratories International during the fourth quarter valued at approximately $26,000. Los Angeles Capital Management LLC bought a new stake in shares of Charles River Laboratories International in the fourth quarter worth $42,000. Sfam LLC purchased a new stake in Charles River Laboratories International during the fourth quarter valued at $43,000. Activest Wealth Management increased its position in Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 218 shares during the last quarter. Finally, Elyxium Wealth LLC bought a new position in Charles River Laboratories International in the fourth quarter valued at about $46,000. 98.91% of the stock is currently owned by institutional investors.

Insiders Place Their Bets In related news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the transaction, the director directly owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In Several brokerages have recently weighed in on CRL. Mizuho increased their price objective on shares of Charles River Laboratories International from $192.00 to $230.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Royal Bank Of Canada initiated coverage on shares of Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price for the company. Barclays upped their target price on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Finally, Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a report on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $220.75.

View Our Latest Stock Report on Charles River Laboratories International

Charles River Laboratories International Trading Down 2.0% Shares of CRL stock opened at $219.91 on Tuesday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The stock has a fifty day simple moving average of $193.76 and a two-hundred day simple moving average of $186.77. The firm has a market capitalization of $10.59 billion, a PE ratio of -58.49, a PEG ratio of 2.50 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52-week low of $144.26 and a 52-week high of $237.86.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The business had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company’s revenue was up 1.2% on a year-over-year basis. During the same period last year, the firm posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, analysts predict that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Charles River Laboratories International Profile (Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

Read More Five stocks we like better than Charles River Laboratories International The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEMicrosoft Corporation $MSFT Shares Sold by Geneva Partners LLC

NEXT HEADLINE »DICK’S Sporting Goods, Inc. $DKS Shares Sold by Bank of New York Mellon Corp

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Charles River Laboratories (CRL - Free Report) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.

This medical research equipment and services provider has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 3.84%.

For the last reported quarter, Charles River came out with earnings of $2.06 per share versus the Zacks Consensus Estimate of $1.96 per share, representing a surprise of 5.10%. For the previous quarter, the company was expected to post earnings of $2.33 per share and it actually produced earnings of $2.39 per share, delivering a surprise of 2.58%.

Price and EPS Surprise

With this earnings history in mind, recent estimates have been moving higher for Charles River. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Charles River currently has an Earnings ESP of +1.43%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner.

Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.

Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company,

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to shareholders.

If you currently own Charles River stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Key Takeaways Charles River is supported by RMS strength, broader CRADL adoption and focused portfolio actions.CRL completed CDMO and Cell Solutions divestitures and repurchased $200M of stock in Q1 2026.CRL faces soft biopharma demand and foreign exchange headwinds that may weigh on 2026 results. Charles River Laboratories International, Inc. (CRL - Free Report) is well-poised to grow in the coming quarters owing to the strength of its Research Models and Services (“RMS”) business and broader CRADL adoption. Strategic deals continue to broaden its capabilities while streamlining its portfolio. The company maintains a solid financial position, which is also highly encouraging. Yet, persistent soft biopharma demand trends and adverse currency swings may hurt Charles River’s results of operations.

Over the past year, this Zacks Rank #3 (Hold) stock has rallied 44.6% compared with the industry’s 9.6% rise and the S&P 500 composite’s 23% growth.

The renowned, non-clinical global drug development company has a market capitalization of $10.87 billion. Charles River has an earnings yield of 4.9%, which compares favorably with the industry’s 4.1% yield. It surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 9.31%.

Let’s delve deeper.

Upsides for CRL StockRMS Prospects Seem Bright: Charles River continues to maintain its position as a global leader in the production and sale of widely used research models. Small research models remain a cost-effective tool for biomedical research, supporting the company’s ability to implement pricing actions across geographies over time.

In the first quarter of 2026, management highlighted continued demand for small models in China from mid-tier biotech and CRO clients and emphasized that RMS results can vary from quarter to quarter based on the timing of large-model shipments. Charles River’s CRADL model also continues to appeal to clients seeking flexible vivarium space without having to build internal infrastructure, with its value proposition becoming even more attractive as clients prioritize capital efficiency.

Image Source: Zacks Investment Research

Strategic Deals Drive Growth: Charles River is reshaping its portfolio to focus on areas where it has differentiated scientific capabilities. The company completed the previously announced divestiture of its contract development and manufacturing organization (CDMO) and Cell Solutions businesses on May 6, 2026.  CRL continues to use collaborations and selective acquisitions to broaden its capabilities across the discovery-to-development continuum while maintaining a more focused go-forward portfolio.

Its strategic collaborations within its CDMO, including partnerships with the Parker Institute for Cancer Immunotherapy, Children's Hospital Los Angeles and the Gazi University Faculty of Medicine, are aimed at advancing novel oncology research and development. In 2025, Charles River participated in several collaborations, including those with Toxys, X-Chem and the Francis Crick Institute, among others.

A Stable Solvency Structure: Charles River exited the first quarter of 2026 with cash and cash equivalents of $191.8 million, and no short-term debt payable on its balance sheet. The company continues to balance investment, shareholder returns and funding needs. Charles River also repurchased $200 million of stock under the $1.0 billion authorization, leaving $800 million remaining at quarter-end. 

Factors Affecting Charles RiverBiopharma Demand Remains Soft: Charles River continues to face a cautious spending environment, particularly among global biopharmaceutical and biotechnology clients within the DSA segment, as customers reassess budgets, reprioritize drug pipelines and manage cost structures. While management characterized the biopharma demand environment as stabilizing, spending levels are yet to return to prior norms.

First-quarter 2026 organic revenues declined 1.5%, reflecting pressure in RMS and discovery services. Management also noted that revenues from small and mid-sized biotech clients dropped during the quarter due to the lagged impact of softer DSA bookings in mid-2025, highlighting that improved funding conditions do not translate into revenues immediately.

Foreign Exchange Can Obscure Underlying Trends: Foreign currency translation increased Charles River’s reported first-quarter 2026 revenues by 2.8%, partially masking the underlying organic decline. Management also lowered its 2026 reported revenue outlook by approximately 50 basis points due to updated foreign exchange assumptions. Given the company’s sizable international footprint, foreign exchange volatility can create discrepancies between reported and organic performance and make period-to-period comparisons more challenging.

CRL Stock Estimate TrendThe Zacks Consensus Estimate for CRL’s 2026 earnings has increased 1 cent to $11.05 in the past 30 days.

The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $3.83 billion, suggesting a 4.5% decrease from the year-ago reported number.

Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .

Globus Medical has an earnings yield of 5.9% compared to the industry’s negative 3.5% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 27.8% against the industry’s 10.9% decline over the past year.

GMED carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Align Technology, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dipped 15.3% against the industry’s 9.1% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.

Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 13.6% against the industry’s negative 3.5% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 33.3% against the industry’s 10.9% decline over the past year.

HomeStock IdeasLong IdeasHealthcare 

SummaryAchieve Life Sciences remains a cytisinicline story, with very positive smoking-cessation data. This also gives cytisinicline some added optionality for vaping.The FDA's CRL appears to be mostly about manufacturing and labeling issues. However, it’s not about a particular cytisinicline efficacy or safety problem.ACHV is currently targeting Q4 2026 resubmission and, assuming everything goes according to plan, it could receive approval by 1H2027.ACHV’s recent capital raise in April also helped their runway and gives them flexibility in case there are more setbacks going forward.As such, I believe ACHV has the resources and ingredients to prove that cytisinicline can work for nicotine addiction. So, I remain bullish on the stock long-term.Iryna Melnyk/iStock via Getty Images

Achieve Life Sciences, Inc. (ACHV) is a pharmaceutical company that is developing cytisinicline. This is a smoking cessation medication, which has so far shown promising results in two Phase 3 trials. In theory, cytisinicline could eventually address both

3.47K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

-

Collaboration supports Charles River’s strategic goals to build deeper client relationships to further modernize R&D through innovative technologies

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly).

"The combination of Charles River’s decades-long expertise in nonclinical testing with TuneLab’s innovative AI/ML models will support the accelerated development of innovative therapeutics."

Share TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data, in exchange for data contributions that improve model performance through federated learning. Participating companies may use the TuneLab prediction models to more rapidly down-select candidate molecules. Through this collaboration, Charles River will provide nonclinical testing services to TuneLab companies.

“The combination of Charles River’s decades-long expertise in nonclinical testing with TuneLab’s innovative AI/ML models will support the accelerated development of innovative therapeutics,” said Dr. Namandjé N. Bumpus, Chief Science and Innovation Officer, Charles River. “TuneLab’s collaborative AI platform democratizes access to pharma-grade tools, relieving a substantial resource burden for biotechs. By layering in Charles River’s industry-leading hands-on research experience, TuneLab participants have access to additional validation that supports discovery decision-making.”

Standardizing protocols with nonclinical testing across the TuneLab ecosystem should enable the AI/ML models to learn more efficiently from the ongoing contributions, improving the models further and increasing the efficiency of the TuneLab platform.

Lilly TuneLab is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.

Charles River remains committed to advancing the validation and acceptance of new approach methodologies (NAMs), including through its Alternative Methods Advancement Project™ (AMAP™) initiative. Together with clients, regulators, and industry, NAMs provide a foundation for a future where more patients gain access to life-saving treatments—safely, swiftly, and with reduced reliance on animal use in research where scientifically appropriate.

About the Alternative Methods Advancement Project (AMAP)

The Alternative Methods Advancement Project (AMAP) is a Charles River-led initiative dedicated to developing New Approach Methodologies (NAMs) and exploring innovative scientific and technological solutions aimed at reducing reliance on traditional animal testing. As we enter the next frontier of drug development, AMAP enables strategic, purpose-driven investment to shape a future in which more patients can access the treatments and medicines they need safely, swiftly, and successfully. AMAP is supported by our global, cross-functional Scientific Advisory Board led by Dr. Namandjé N. Bumpus.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

More News From Charles River Laboratories International, Inc.

Back to Newsroom

Key Takeaways CRL posted Q1 adjusted EPS of $2.06 and revenues of $995.8M, both above estimates.Charles River saw gross margin fall 269 bps and adjusted operating margin contract 64 bps.CRL reaffirmed 2026 guidance and completed the CDMO and Cell Solutions divestiture. Charles River Laboratories International, Inc. (CRL - Free Report) reported first-quarter 2026 adjusted earnings per share (EPS) of $2.06, down 12% year over year. The figure surpassed the Zacks Consensus Estimate by 5.1%.

On a GAAP basis, the company reported a loss of 30 cents per share compared with the year-ago quarter’s earnings of 50 cents.

CRL’s RevenuesRevenues totaled $995.8 million, which beat the Zacks Consensus Estimate by 2.5%. The top line rose 1.2% from the year-ago quarter’s level (down 1.5% organically, excluding the impact of foreign currency translation and the divestiture of a small Safety Assessment site in 2024).

Following the announcement, CRL shares fell 0.7% in the pre-market trading today.

CRL’s Q1 Segmental Performance in DetailThe company reports under three segments — Research Models and Services (“RMS”), Discovery and Safety Assessment (“DSA”) and Manufacturing Solutions.

RMS’ revenues totaled $208.4 million, down 2.2% year over year (down 5.5% organically). The organic decrease was mainly due to lower revenues for large research models and small research models in North America. Our model estimated RMS’ revenues to be $209.8 million in the first quarter.

DSA’s revenues amounted to $596.9 million, up 0.7% year over year (down 1.4% organically). The organic decline in revenues was primarily due to lower revenues for discovery services, partly from the impact of prior site consolidation activities. Our model projected revenues of $579.9 million for this segment.

Manufacturing Solutions’ revenues totaled $190.5 million, up 6.8% year over year (up 2.9% organically). The organic growth was due to higher revenues in the Microbial Solutions business. Our model projected revenues to be $194.9 million for the first quarter.

CRL’s Margin PerformanceThe gross profit in the reported quarter was $294.7 million, down 7.3% from the prior-year quarter’s level. The gross margin of 29.6% fell 269 basis points (bps) year over year.

Selling, general & administrative expenses dropped 10.3% year over year to $159.4 million. The adjusted operating profit totaled $135.2 million, down 3.4% from the prior-year quarter’s level. The adjusted operating margin contracted 64 bps to 13.6%.

CRL’s Liquidity PositionCharles River exited the first quarter of 2026 with cash and cash equivalents of $191.8 million compared with $213.8 million at the end of 2025.

Cumulative net cash provided by operating activities at the end of the first quarter was $41.1 million compared with $171.7 million a year ago.

During the first quarter of 2026, Charles River repurchased 1.1 million shares for a total of $200.0 million. As of March 28, 2026, it had $800.0 million remaining under its $1.0 billion stock repurchase authorization that was approved by the board of directors on Oct. 29, 2025.

CRL’s Divestiture UpdateOn May 6, 2026, Charles River completed the divestiture of the CDMO and Cell Solutions businesses to GI Partners. It expects to complete the sale of certain European Discovery Services sites in May 2026. These strategic transactions are expected to help the company refocus its comprehensive portfolio on core competencies and drive synergistic growth in areas in which it has differentiated scientific expertise.

Charles River’s 2026 GuidanceThe company last updated its full year guidance on Feb. 25, 2026, including the expected impact of the completed divestiture of the CDMO and Cell Solutions businesses, and the planned divestiture of certain European Discovery Services sites in May 2026.

Reported revenues for the year are now expected to grow (5.5)% - (4)%, from the previous (5.0)% - (3.5)% forecast. The Zacks Consensus Estimate for 2026 revenues is pegged at $3.97 billion, implying a 1.3% fall. 

Adjusted EPS for 2026 is expected in the range of $10.80-$11.30. The Zacks Consensus Estimate for the metric is pegged at $10.97.

Our Take on CRLCharles River exited the first quarter of 2026 with earnings and revenues beating estimates. The company delivered on the quarter’s targets and remains well-positioned to generate improving results throughout the year. By segment, organic revenue growth in the Manufacturing Solution was more than offset by organic revenue declines in the RMS and DSA segments. The contraction of both margins in the quarter is also discouraging.

Charles River reduced its 2026 reported revenue outlook by roughly 50 bps to reflect recent changes in assumptions for foreign exchange rates.

CRL’s Zacks Rank and Key Picks

Charles River currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are BrightSpring Health Services (BTSG - Free Report) , Intuitive Surgical (ISRG - Free Report) and Labcorp Holdings (LH - Free Report) .

BrightSpring Health Services, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted EPS of 36 cents, which surpassed the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion beat the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

BTSG has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth. The company topped earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 14.61%.

Intuitive Surgical,carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $2.50, exceeding the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion outpaced the Zacks Consensus Estimate by 6.2%.

ISRG has an earnings yield of 2.1% compared to the industry’s negative 0.9% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.

Labcorp,carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $4.25, exceeding the Zacks Consensus Estimate by 3.8%. Revenues of $3.54 billion outperformed the Zacks Consensus Estimate by 1%.

LH has an earnings yield of 6.9% compared with the industry’s 4.5% yield. The company’s earnings topped estimates in each of the trailing four quarters, the average surprise being 3.31%.

Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript

Charles River Laboratories International, Inc. (NYSE:CRL) posted upbeat earnings for the first quarter, but lowered its FY2026 forecast on Thursday.

The company posted adjusted EPS of $2.06, beating market estimates of $1.94. The company's sales came in at $995.830 million versus expectations of $977.486 million.

Charles River slashed its FY2026 GAAP EPS guidance from $6.30-$6.80 to $5.35-$5.85. The company also lowered its FY2026 sales guidance from $3.814 billion-$3.874 billion to $3.794 billion-$3.854 billion.

Birgit Girshick, Chief Executive Officer, said, “We are pleased to deliver on our first-quarter financial targets, and remain well positioned to generate improving results over the course of the year. Our confidence is supported by a DSA demand environment that is tracking to our expectations, resulting in solid bookings in the first quarter, as well as the successful execution of our strategy.”

Charles River shares fell 2.4% to trade at $177.25 on Friday.

These analysts made changes to their price targets on Charles River following earnings announcement.

Evercore ISI Group analyst Ross Muken maintained Charles River with an Outperform rating and raised the price target from $200 to $220. Barclays analyst Luke Sergott maintained the stock with an Overweight rating and raised the price target from $210 to $220. Considering buying CRL stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 322

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

Have you evaluated the performance of Charles River Laboratories' (CRL - Free Report) international operations for the quarter ending March 2026? Given the extensive global presence of this medical research equipment and services provider, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.

In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For investors, the key is to grasp how reliant a company is on overseas markets, as this provides insights into the durability of its earnings, its ability to exploit different economic cycles, and its overall growth capabilities.

Being present in foreign markets serves as protection against local economic declines and helps benefit from more rapidly expanding economies. Yet, such expansion also introduces challenges related to currency fluctuations, geopolitical uncertainties and varied market behaviors.

Our review of CRL's last quarterly performance uncovered some notable trends in the revenue contributions from its international markets, which are commonly analyzed and tracked by Wall Street experts.

The company's total revenue for the quarter stood at $995.83 million, increasing 1.2% year over year. Now, let's delve into CRL's international revenue breakdown to gain insights into the significance of its operations beyond home turf.

A Dive into CRL's International Revenue TrendsCanada generated $109.57 million in revenues for the company in the last quarter, constituting 11% of the total. This represented a surprise of -2.94% compared to the $112.88 million projected by Wall Street analysts. Comparatively, in the previous quarter, Canada accounted for $123.28 million (12.4%), and in the year-ago quarter, it contributed $125.35 million (12.7%) to the total revenue.

Europe accounted for 27.9% of the company's total revenue during the quarter, translating to $277.58 million. Revenues from this region represented a surprise of +5.64%, with Wall Street analysts collectively expecting $262.77 million. When compared to the preceding quarter and the same quarter in the previous year, Europe contributed $279.9 million (28.2%) and $263.25 million (26.8%) to the total revenue, respectively.

Of the total revenue, $9.4 million came from Other International, including Brazil and Israel during the last fiscal quarter, accounting for 0.9%. This represented a surprise of -20.98% as analysts had expected the region to contribute $11.89 million to the total revenue. In comparison, the region contributed $16.79 million, or 1.7%, and $16.67 million, or 1.7%, to total revenue in the previous and year-ago quarters, respectively.

During the quarter, Asia Pacific contributed $55.48 million in revenue, making up 5.6% of the total revenue. When compared to the consensus estimate of $42.48 million, this meant a surprise of +30.61%. Looking back, Asia Pacific contributed $56.91 million, or 5.7%, in the previous quarter, and $41.94 million, or 4.3%, in the same quarter of the previous year.

International Revenue PredictionsWall Street analysts expect Charles River to report $1 billion in total revenue for the current fiscal quarter, indicating a decline of 2.7% from the year-ago quarter. Canada, Europe, Other International, including Brazil and Israel and Asia Pacific are expected to contribute 12.4% (translating to $124.71 million), 27.1% ($272.09 million), 0.7% ($6.85 million), and 5.4% ($54.2 million) to the total revenue, respectively.

For the entire year, the company's total revenue is forecasted to be $4.01 billion, which is a reduction of 0.1% from the previous year. The revenue contributions from different regions are expected as follows: Canada will contribute 12.2% ($489.12 million), Europe 27% ($1.08 billion)Other International, including Brazil and Israel 1.1% ($45.04 million) and Asia Pacific 5% ($200.56 million) to the total revenue.

Final ThoughtsCharles River's reliance on international markets for revenues offers both opportunities and risks. Hence, keeping an eye on its international revenue trends could significantly help forecast the company's prospects.

In an environment where global interconnections and geopolitical skirmishes are intensifying, Wall Street analysts keep a keen eye on these trends, particularly for firms with overseas operations, to adjust their earnings predictions. Moreover, a range of other aspects, including how a company fares in its home country, significantly affects these projections.

Here at Zacks, we put a great deal of emphasis on a company's changing earnings outlook, as empirical research has shown that's a powerful force driving a stock's near-term price performance. Quite naturally, the correlation is positive here -- an upward revision in earnings estimates drives the stock price higher.

The Zacks Rank, our proprietary stock rating mechanism, demonstrates a notable performance history confirmed through external audits. It effectively utilizes the power of earnings estimate revisions to act as a predictor of a stock's price performance in the near term.

At present, Charles River holds a Zacks Rank #3 (Hold). This ranking implies that its near-term performance might mirror the overall market movement. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Examining the Latest Trends in Charles River Laboratories' Stock ValueOver the past month, the stock has seen an increase of 1.1% in its value, whereas the Zacks S&P 500 composite has posted an increase of 9.1%. The Zacks Medical sector, Charles River's industry group, has descended 2.9% over the identical span. In the past three months, there's been an increase of 10.1% in the company's stock price, against a rise of 7.1% in the S&P 500 index. The broader sector has declined by 9.8% during this interval.